As push to disrupt PD-(L)1 pricing heats up, Checkpoint trumpets a pivotal success
The crowded PD-(L)1 market has proven lucrative for biopharma’s earliest entrants like Merck’s Keytruda and Bristol Myers Squibb’s Opdivo, but newer drugs have struggled to pry away market share. One strategy being undertaken by some biotech is to offer the drugs at a lower price, and one such company claimed it’s now one step closer to approval.
Checkpoint Therapeutics revealed topline pivotal data for its anti-PD-L1 antibody cosibelimab Tuesday morning, saying the candidate achieved a 47.4% overall response rate in metastatic cutaneous squamous cell carcinoma patients. The biotech has previously indicated it could offer the drug at a 20% to 30% discount from the usual $150,000 price tag.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 159,000+ biopharma pros reading Endpoints daily — and it's free.